Arthrosis
0
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
MedactaSwitzerland - Castel San Pietro
3 programsAMIStem-PN/A1 trial
Quadra P antevertedN/A1 trial
SMS femoral stemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
MedactaQuadra P anteverted
MedactaAMIStem-P
MedactaSMS femoral stem
Clinical Trials (3)
Total enrollment: 1,400 patients across 3 trials
The Medacta Quadra-P Anteverted Study
Start: Jul 2021Est. completion: Jul 2032300 patients
N/AActive Not Recruiting
The Medacta International AMIStem-P Post-Marketing Surveillance Study
Start: Apr 2019Est. completion: Dec 2032550 patients
N/AActive Not Recruiting
The Medacta International SMS Post-Marketing Surveillance Study
Start: Jul 2015Est. completion: Jul 2032550 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,400 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.